Please login to the form below

Not currently logged in
Email:
Password:

HM71224

This page shows the latest HM71224 news and features for those working in and with pharma, biotech and healthcare.

Lilly drops Hanmi-partnered arthritis drug

Lilly drops Hanmi-partnered arthritis drug

Eli Lilly has decided to abandon trials of its BTK inhibitor HM71224 in rheumatoid arthritis after an interim look at its prospects. ... Lilly licensed HM71224 (LY3337641) from South Korean biotech Hanmi Pharmaceutical in 2015 for $50m upfront and

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics